Johanna Midelet
Director, Bioconjugation & Synthetic Chemistry Abzena
Seminars
Tuesday 13th October 2026
Improving the Delivery of Next-Generation ADCs with ThioBridge Site-Specific Conjugation Technology
11:30 am
- Delving into mechanistic insights of ThioBridge and advantages over conventional stochastic conjugation approaches, demonstrated through in vitro and in vivo ADC stability data
- Exploring how DAR can be precisely controlled using ThioBridge to optimize ADC therapeutic activity
- Assessing design strategies for optimizing linker-payload combinations to improve in vivo efficacy, supported by relevant preclinical data
- Manufacturing Considerations: Understanding key aspects of ThioBridge linker-payload and ADC manufacturing processes
Wednesday 14th October 2026
Leveraging Advanced Bioconjugates Expertise to Design & Develop Next-Generation AOCs
9:30 am
- Contextualizing the emergence of AOCs to enhance therapeutic index of antisense oligonucleotides with improved biodistribution, cellular uptake and pharmacological activity
- Understanding how AOCs require different approaches to conjugation chemistry, linker selection and analytical characterization to translate into clinic-ready mechanisms
- Applying extensive conjugation expertise and exploring real-world case studies to design and develop next-generations AOCs, highlight the key decisions that help de-risk development and shorten the path to the clinic
